Previous close | 39.82 |
Open | 40.10 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 40.10 - 40.10 |
52-week range | 28.09 - 40.96 |
Volume | |
Avg. volume | 4 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Oliver thinks this growth stock could capitalise on the growing artificial intelligence revolution. However, he says the valuation could prove troubling. The post This growth stock could be positioned to capitalise on massive AI popularity appeared first on The Motley Fool UK.
LexisNexis® Risk Solutions, a leading provider of data and analytics, today announced that its LexisNexis® Health Equity and Inclusion Insights has been selected as the winner of the "Best Healthcare Big Data Solution" award in the 8th annual MedTech Breakthrough Awards, an independent market intelligence awards programs that recognizes the top companies, technologies and products in the global digital health and medical technology market.
Harvey Jones is still kicking himself for failing to buy these two top FTSE 100 growth stocks last June. Now he's just waiting for his moment. The post Are these 2 top-performing UK growth stocks set to smash the index all over again? appeared first on The Motley Fool UK.